Iniparib

Drug Profile

Iniparib

Alternative Names: BSI-201; SAR-240550

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator BiPar Sciences
  • Developer BiPar Sciences; National Cancer Institute (USA); Sanofi
  • Class Antineoplastics; Benzamides; Iodobenzenes; Nitro compounds; Small molecules
  • Mechanism of Action Cell cycle inhibitors; H2AFX protein stimulants; Tumour protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain metastases; Breast cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer

Most Recent Events

  • 01 Feb 2017 Sanofi completes the phase II SOLTI NEOPARP trial in Breast cancer (Combination therapy, Neoadjuvant therapy) in France, Germany and Spain (IV, Infusion) (NCT01204125)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Jun 2015 Sanofi completes a phase I/II trial in Glioblastoma in USA (NCT00687765)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top